W. Yen

发表

Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.

W. Lamph, R. Bissonnette, R. Cesario, 2006, Cancer letters.

Role of Na+ in the asymmetric paracellular transport of 4-phenylazobenzyloxycarbonyl-L-Pro-L-Leu-Gly-L-Pro-D-Arg across rabbit colonic segments and Caco-2 cell monolayers.

V. H. Lee, W. Yen, 1995, The Journal of pharmacology and experimental therapeutics.

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

M. Fischer, J. Lewicki, A. Gurney, 2012, Proceedings of the National Academy of Sciences.

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

M. Fischer, J. Lewicki, A. Gurney, 2011, Cancer research.

Abstract 1907: Wnt pathway antagonist OMP-54F28 (FZD8-Fc) inhibits tumor growth and reduces tumor-initiating cell frequency in patient-derived hepatocellular carcinoma and ovarian cancer xenograft models

M. Fischer, J. Lewicki, A. Gurney, 2014 .

Abstract A30: Predictive and pharmacodynamic biomarkers of vantictumab (OMP-18R5; anti-Frizzled) in non-small cell lung cancer

M. Fischer, J. Lewicki, T. Hoey, 2015 .

LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo.

M. D. Leibowitz, L. De Grandpré, B. Bebo, 2008, Endocrinology.

Anti-DLL4 HasBroad SpectrumActivityinPancreatic Cancer DependentonTargetingDLL4-NotchSignalinginBothTumor and Vasculature Cells

Edward J. Kim, M. Fischer, J. Lewicki, 2012 .

Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model.

H. Hsieh, C. Chen, C. Shih, 2021, Journal of medicinal chemistry.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

Michael F Clarke, Sanjeev Satyal, M. Clarke, 2009, Cell stem cell.

RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations

M. Fischer, T. Hoey, F. Cattaruzza, 2017, Scientific Reports.

Differential Effect of Taxol in Rat Primary and Metastatic Prostate Tumors: Site-Dependent Pharmacodynamics

J. Au, M. Wientjes, W. Yen, 1996, Pharmaceutical Research.

WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death

M. Fischer, J. Lewicki, A. Gurney, 2017, Science Advances.

Abstract 4367: Discovery and evaluation of pharmacodynamic and predictive biomarkers for anti-RSPO3, a treatment that reduces tumor growth and cancer stem cell frequency in patient derived xenograft tumor models

M. Fischer, J. Lewicki, A. Gurney, 2015 .

Abstract 4652: Effects of anti-DLL4 treatment on non-small cell lung cancer (NSCLC) human xenograft tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells

Edward J. Kim, M. Fischer, J. Lewicki, 2012, Clinical Cancer Research.

Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma

W. Lamph, William W. Lamph, Wan-ching Yen, 2004, Breast Cancer Research and Treatment.

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

H. Hsieh, W. Yen, You-Liang Lai, 2022, Journal of biomedical science.

Abstract 3357: Targeting cancer stem cells by an anti-DLL4 antibody inhibits epithelial-to-mesenchymal transition, delays tumor recurrence and overcomes drug resistance in breast and pancreatic cancer

M. Fischer, J. Lewicki, A. Gurney, 2012 .

Abstract 2834: Anti-DLL4 treatment inhibits melanoma tumor growth, recurrence, metastases, and reduces frequency of cancer stem cells in a clinically relevant tumor model in NOD/SCID mice

M. Fischer, J. Lewicki, A. Gurney, 2011 .

A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer

W. Lamph, R. Bissonnette, A. Negro-Vilar, 2004, Clinical Cancer Research.

Intestinal paracellular peptide transport: mobilization of intracellular calcium as a mechanism of tight junctional opening by 4-phenylazobenzoxycarbonyl–Pro–Leu–Gly–Pro–d-Arg (Pz-peptide) in the rabbit descending colon and Caco-2 cell monolayers

V. H. Lee, W. Yen, Y. Higashi, 1997 .

Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.

S. Ng, A. Negro-Vilar, Patricia Tooker, 2007, Cancer research.

The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.

W. Lamph, R. Bissonnette, A. Negro-Vilar, 2005, Lung cancer.

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

M. Fischer, J. Lewicki, A. Gurney, 2016, Cancer research.

Different pH Dependency of Mitomycin C Activity in Monolayer and Three-Dimensional Cultures

Thomas D. Schmittgen, J. Au, W. Yen, 1996, Pharmaceutical Research.

Cancer Therapy : Preclinical Anti-DLL 4 HasBroad SpectrumActivity in Pancreatic Cancer DependentonTargetingDLL 4-NotchSignaling inBothTumor and Vasculature Cells

Edward J. Kim, M. Fischer, J. Lewicki, 2012 .

A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer

W. Lamph, W. Yen, 2006, The Prostate.

The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma

W. Lamph, W. Yen, 2005, Molecular Cancer Therapeutics.

A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours

W. Lamph, A. Negro-Vilar, W. Yen, 2006, British Journal of Cancer.

Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency

M. Fischer, J. Lewicki, A. Gurney, 2015 .

Abstract 3129: Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts

M. Fischer, J. Lewicki, A. Gurney, 2016 .

ASelective RetinoidXReceptorAgonist Bexarotene (LGD1069,Targretin) Prevents andOvercomes

W. Lamph, W. Yen, 2005 .

Abstract 404: Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

M. Fischer, J. Lewicki, A. Gurney, 2011, Cancer research.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types

J. Lewicki, A. Gurney, T. Hoey, 2015 .